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Identification and Function of Ets Target Genes Involved in Lung Cancer Progression
Introduction: Improved understanding of the molecular changes associated with lung tumorigenesis is urgently needed to explore novel venues for diagnostics and treatment. Ets proteins are extremely important in human cancer progression . 27 human Ets family members have been identified, and in some systems multiple Ets factors act in concert to regulate pathways involved in tumorigenesis . One model of metastasis proposes that a subset of tumor cells within epithelial malignancies acquires the ability to disseminate by undergoing an epithelial-mesenchymal transition (EMT). These cells are characterized by (1) loss of cell-cell attachments, E-cadherin expression, and apical-basal polarity, and (2) appearance of mesenchymal differentiation properties . We hypothesize that Ets1 contributes to lung tumorigenesis by binding to specific promoters that control transcription of genes involved in EMT. To test our hypothesis, we used a mouse lung cancer model with metastasis driven by conditionally activated Kras and concurrent tumor suppressor Lkb1 loss (Kras G12D /Lkb1 L/L model) and a similar model but one that does not metastasize, driven by conditionally activated Kras alone (Kras G12D model). We measured expression of Ets1 and Twist in KrasG12D /Lkb1L/L and KrasG12D cell lines. Using ChIP assays, we determined whether Ets1 binds Twist1. We determined whether silencing and/or overexpressing Ets1 alters Twist1 expression. In this past year, we have (1) characterized Twist-1 positive epithelial and stromal cells (2) performed functional analysis of Twist1 using in vitro assays including migration and invasion assays, (3) performed overexpression studies to validate Ets1 regulation of Twist1 and (4) have started preparing and submitting grant proposals based on our significant findings from this award. Our findings to date are summarized in this report.
Body:
To test our hypothesis that Ets1 contributes to lung tumorigenesis by binding to specific promoters that control transcription of genes involved in EMT, we proposed the specific aims below. Our progress and findings associated with each specific aim are outlined below. For detailed description of methods, figures, and figure legends, please see Appendix 4 and Supporting Data. 
SA1. Determine the mechanism of increased Ets1 expression in the metastatic Kras
G12D /Lkb1L/L model compared to the non-metastatic Kras G12D model.
1a.
Determine whether the inactivation of Lkb1 increases the induction and protein stability of Ets1 and Pea3.
Oct 201-8 Oct, 2012 update
We have no further updates to report for this past progress report year. In year 3,
we will determine if in Kras G12D primary tumors, Pea3 P04 is degraded and therefore not detected. We expect that proteosome inhibition with MG-132 will result in a significant increase in Pea3 protein levels. primary tumors (Fig 1a) . To determine if cell types expressing Ets1 differ in the two models, we performed immunohistochemistry on Kras G12D and Kras G12D /Lkb1 L/L specimens (Fig 1b) . In Kras G12D primary tumors, Ets1 protein expression could not be detected. In Kras G12D /Lkb1 L/L primary tumors and metastatic lymph nodes, scattered epithelial cancer cells express Ets1.
Although Pea3 is expressed in both models, there were no differences in Pea3 mRNA expression between Kras G12D and Kras G12D /Lkb1 L/L specimens (Fig 1a) . Since the normal function of Lkb1 gene is to phosphorylate Pea3, targeting it for proteosomemediated degradation, we hypothesized that Kras G12D /Lkb1 L/L mice might have increased Pea3 protein expression. In future studies (years 2 and 3), we will determine if in Kras G12D primary tumors, Pea3 P04 is degraded and therefore not detected. We expect that proteosome inhibition with MG-132 will result in a significant increase in Pea3 protein levels. that are known to directly bind to Ets1 include HIF-1, Ets1, AP-1, wildtype p53 (but not mutant p53) and RAR (see cartoon below). In year 3 and/or in future studies we will determine if HIF-1 and/or other Ets proteins transactivate Ets-1.
Oct 2010 -30 Sept 201update
We had no updates on SA1b last year as this aim had not yet been started.
Factors that modulate Ets1 expression. Transcription factors that directly bind to the Ets1 promoter are shown in light yellow, kinases are in orange, growth factors and other factors are in green. AP-1 = activator protein 1, ERK1/2 = extracellular-signal-regulated kinase 1/2, HGF = hepatocyte growth factor, HIF-1 = hypoxia-inducible factor 1, PDGF = platelet derived growth factor, PKC = protein kinase C, RA = retinoic acid, RAR = retinoic acid receptor, TNFα = tumor necrosis factor α, wt p53 = wildtype p53. Dittmer, J. and progression to metastatic disease. While we hope to be able to complete this aim in year 3, analyzing our models may not be completed within our timeframe. We will therefore apply for further grant funding to complete the objectives in this specific aim.
SA3. Determine whether Lkb1 mutations associate with Ets1 and Pea3 expression
and activity in tumors of lung cancer patients.
3a. Using human lung cancer specimens, determine whether Ets1 and Pea3 are differentially expressed between patients with and without the Lkb1 inactivating mutation using QRT-PCR, western blot, and immunohistochemistry (IHC).
Oct 201-8 Oct, 2012 update
We will determine if Ets1 and Pea3 are differentially expressed in patients with and without Lkb1 inactivating mutation in year 3. 
Conclusions:
Using human lung cancer cell lines, we show that Ets1 regulates the Twist1 expression. We show that in human lung tumors, Twist1-positive cells are preferentially localized in stroma adjacent to clusters of cancer cells. Although these cells have a fibroblast-like morphology, it is possible that they are, or are derived from cancer cells that have undergone a morphological change via EMT. Preliminary studies suggest that in primary tumors, the expression pattern of Twist1, Ets1 and the mesenchymal marker S100A4 (fibroblast-specific protein 1 (FSP1)] positively correlate. Further characterization of these Twist1-positive epithelial and stromal cells will be the focus of future studies. Identifying upstream Twist1 activators and downstream targets will be critical for understanding the molecular mechanisms underlying metastasis. Tumor metastasis is the primary cause of treatment failure and death for most cancer patients. Transcription factors including, but not limited to, Snail, Zeb1, Slug, and TWIST have been shown to induce epithelial-mesenchymal transition (EMT), a process that is regarded as essential for metastasis. These transcription factors exert their effects mainly through the repression of E-cadherin. TWIST, a highly conserved basic helix-loop-helix (bHLH) transcription factor, is a master regulator of embryonic morphogenesis. Recently, it has been shown to be a key player in mediating cancer metastasis in a number of cancer types such as ovarian cancer, hepatocellular carcinoma, melanoma, prostatic adenocarcinoma, and invasive lobular breast carcinoma. The aim of our study was to evaluate the prognostic value of TWIST expression in patients with resectable non-small cell lung cancers (NSCLC) in relation to staging, risk of metastasis, and different histologic subtypes.
In agreement with recent studies stating prognoses varies with histologic subtypes, our data shows significant difference in Twist expression amongst corresponding subtypes. A significant difference in Twist expression was noted in poorly differentiated adenocarcinomas, as compared to moderately and well-differentiated forms. Twist was found to be over-expressed in tumors with nodal involvement compared to those without. In conclusion, our findings suggest that high Twist expression is an independent marker in NSCLC prognosis, and can be useful in risk stratification and tailoring therapeutic modalities in resectable NSCLC. 
INTRODUCTION
Metastasis is a multistep process during which cancer cells disseminate from the site of primary tumors and establish secondary tumors in distant organs, although other mechanisms (tumor stem cells) of establishing metastases have been proposed. Ets proteins are extremely important in human cancer progression . 27 human Ets family members have been identified, and in some systems multiple Ets factors act in concert to regulate pathways involved in tumorigenesis .
In lung cancer, increased Ets1 and Pea3 expression, often called "pro-metastatic" Ets proteins, is associated with poor prognosis (Yamaguchi et al., 2007) . Introducing the Pea3 gene into non-small-cell lung cancer (NSCLC) cell lines lacking endogenous Pea3 expression causes increased motility and invasiveness (Hakuma et al., 2005) . Elevated Ets1 expression has been observed in invasive and metastatic tumors including those of breast, lung, and colon Sasaki et al., 2001 ). The complete pool of Ets1 targets is unknown but Ets1 regulates expression of proteases including urokinase plasminogen activator (uPA) and matrix metalloprotease family members (Mmps 1, 3, 7, 9 and 13) that are required for tumor cells to degrade and invade surrounding extracellular matrix (Sementchenko and Watson, 2000) .
One model of metastasis proposes that a subset of tumor cells within epithelial malignancies acquires the ability to disseminate by undergoing an epithelialmesenchymal transition (EMT). These cells are characterized by (1) loss of cell-cell attachments, E-cadherin expression, and apical-basal polarity, and (2) appearance of mesenchymal differentiation properties . EMT is regulated by several transcription factor families, including basic helix-loop-helix factors (Twist1 and E12/E47), zinc finger proteins (Snail1 and Snail2), and two-handed zinc family factors [Sip1 (Zeb2) and Sip2 (Zeb1) We hypothesize that Ets1 contributes to lung tumorigenesis by binding to specific promoters that control transcription of genes involved in EMT. Ets proteins positively or negatively regulate expression of genes involved in proliferation, development, and transformation (Sharrocks, 2001 ). The regulatory specificity of individual Ets members comes from their cell/tissue patterns of expression, post-translational modifications, interactions with partner proteins, and base-pair differences surrounding the core consensus sequence (Hollenhorst et al., 2005) . Ets proteins bind to DNA sequences containing a GGAA/T core motif, with flanking sequences contributing to specificity of different members (Sharrocks, 2001 (Yang et al., 2006) .
In this report, we correlate expression patterns of Twist1 and Ets1 in human and mouse lung cancer specimens by immunohistochemistry. Using mouse and human lung cancer cell lines, we show that Ets1 regulates Twist1 expression. Chromatin immunoprecipitation assays confirm binding of Ets1 to the Twist1 promoter. Silencing Ets1 expression decreases Twist1 mRNA and protein expression. siRNA-mediated repression of Ets1 and Twist1 results in decreased migration and invasion in metastatic mouse cell lines. We speculate that therapeutic targeting of EMT activators and/or their regulators could be useful to impair EMT, and thus tumor metastasis.
RESULTS
Murine Kras G12D /Lkb1 L/L primary tumors and metastases, compared to Kras G12D primary tumors, have increased Ets1 mRNA by microarray analysis and both increased Ets1and Pea3 protein expression by immunohistochemistry
Gene expression microarray analysis show increased Ets1 expression in Kras
L/L primary tumors and metastases compared to Kras G12D primary tumors (Fig 1a) . To determine if cell types expressing Ets1 differ in the two models, we performed immunohistochemistry on Kras G12D and Kras G12D /Lkb1 L/L specimens (Fig 1b) . In Kras Although Pea3 is expressed in both models, there were no differences in Pea3 mRNA expression between Kras G12D and Kras G12D /Lkb1 L/L specimens (Fig 1a) . Since the normal function of Lkb1 gene is to phosphorylate Pea3, targeting it for proteosomemediated degradation, we hypothesized that Kras G12D /Lkb1 L/L mice might have increased Pea3 protein expression. In Kras G12D primary tumors, Pea3 protein expression could not be detected by immunohistochemistry (Fig 1b) . One plausible explanation is that in Kras G12D mice, wildtype Lkb1 phosphorylates Pea3 and either (1) the Pea3 antibody cannot detect Pea3 P04 or (2) Pea3 P04 is degraded and therefore not detected. In Kras G12D /Lkb1 L/L primary tumors and lymph nodes, scattered epithelial cancer cells express Pea3 (Fig 1b) .
Twist1 staining positively correlates with Ets1 and Pea3 immunostaining in mouse lung tumor specimens.
Previously, gene expression microarray analysis showed increased Twist1 expression in Kras G12D /Lkb1 L/L compared to Kras G12D tumor specimens (Carretero et al., 2010). We performed immunohistochemistry for Twist1 on Kras G12D and Kras
G12D
/Lkb1 L/L specimens (Fig 1b) . Twist1 is not detected in Kras G12D primary tumors. In Kras G12D /Lkb1 L/L primary tumors, Twist1 is detected in scattered tumor epithelial cells (Fig 1b) . In metastatic lymph nodes, positive Twist1 staining is detected in tumor epithelial cells and in scattered surrounding stromal cells.
Ets1 binds to the mouse Twist1 promoter.
Cell lines derived from Kras G12D /Lkb1 L/L (KW-821) and Kras G12D (KW-634) tumors markedly differ in Twist1 mRNA levels (Fig 2a) . KW-821 cells express higher levels of Twist1 mRNA compared to KW-634 cells by QRT-PCR. We performed ChIP assays in KW-821T and KW-821LN cell lines (Fig 2b) . Immunoprecipitated samples using IgG or Ets1 antibodies show that Ets1 binds to the Twist1 promoter in both KW-821T and KW-821LN cells. For negative control (Twist1 promoter sequences to which Ets1 does not bind), there is no difference between IgG and Ets1 (data not shown).
Silencing Ets1 results in a statistically significant decrease in Twist1 mRNA and protein levels.
siRNA mixture targeting Ets1 or non-targeting siRNA control were transfected into KW-821T and KW-821LN cells. We confirm effective knockdown of Ets1 by QRT-PCR and western analysis (Fig 3) . Silencing Ets1 results in a statistically significant decrease in Twist1 mRNA and protein levels in both cell lines (Fig 3) .
Silencing either Twsit1 or Ets1 decreases migration and invasion in cell lines derived from Kras
G12D /Lkb1 L/L primary and metastatic cells.
Cells were transfected with siRNAs (siRNA-Ets1, siRNA-Twist1, and siRNAcontrol), and then seeded in Matrigel-coated invasion or migration chambers for 24 h. Extent of invasion (A) and migration (B) were expressed as an average number of cells per microscopic field. Silencing Twist1 or Ets1 decreases migration and invasion in KW-821 (T and LN) cells (Fig 4) .
Twist1 staining is predominately localized to stromal cells adjacent to tumor epithelial cells in human lung cancer specimens.
Twist1 immunohistochemistry was performed on 30 primary human tumors (5 well-, 15 moderate-, and 10 poorly-differentiated adenocarcinomas). Twist1 is detected in 23/30 primary tumors. Twist1 is detected just in stromal cells surrounding tumor epithelial cells in 15/23 specimens. 1 primary tumor specimen stains positive only in tumor epithelial cells. In 7/23 Twist1-positive specimens, staining is detected in both epithelial and surrounding stromal cells (Figure 5a and b) . In stromal cells, Twist1 is detected in scattered cells which appear to be fibroblasts by morphology. When Twist1 is detected in epithelial tumor cells, it is preferentially observed in marginal regions of cancer foci and is predominately nuclear. In areas of adjacent normal lung, alveolar epithelial and fibroblast cells do not express Twist1 (data not shown).
15 /30 specimens had patient-matched lymph node metastasis. In all 15 specimens with matched lymph node metastasis, Twist1 is detected in primary tumors, metastatic lymph nodes, or both (Fig 5b) . 3/15 patients express Twist1 in just lymph nodes; 3/15 patients stain positive in just primary tumors; and 9/15 express Twist1 in both primary tumor and metastatic lymph nodes. 9/12 metastatic lymph nodes stain 
Twist1 staining positively correlates with Ets1 immunostaining in human primary tumor specimens.
We characterized the expression pattern of Ets1 and Twist1 in 10 primary tumors (5 primary tumors without LN metastasis; 5 primary tumors with LN metastasis). In primary tumors the expression pattern of Twist1 and Ets1 positively correlate. In Twist1-positive stromal cells, Ets1 expression is detected in stromal cells. In Twist1-positive tumor epithelial nuclei, Ets1 is detected in tumor epithelial nuclei (Fig 5a) .
Ets1 binds to the human Twist1 promoter.
We performed ChIP assays in human (A549 and NCI-H1299) cell lines to confirm Ets protein binding to the Twist1 promoter (Fig 6) . Sonicated cell extracts were immunoprecipitated using IgG or Ets1 antibodies and analyzed by PCR for the Twist1 promoter spanning the Ets1 site. Figure 6 is a representative gel showing that Ets1 binds to the Twist1 promoter in both cell lines. For negative control (Twist1 promoter sequences to which Ets1 do not bind), there is no difference between IgG and specific antibodies (data not shown).
There are over 30 Ets cis-elements in the mouse Twist1 promoter and 11 Ets ciselements in the human promoter. Due to variable sizes of promoter DNA fragments generated when DNA is sheared (500 bp to 1kb) in ChIP assays, these experiments can only determine that Ets1 binds the promoter somewhere within the region of average size fragments obtained and cannot identify specific sites that might be utilized preferentially nor can they indicate how many sites are occupied simultaneously.
Silencing Ets1 decreases Twist1 mRNA and protein levels in human cell lines.
We transfected an siRNA mixture targeting Ets1 or non-targeting siRNA control into NCI-H1299 (high Ets1-expressing) cells. We confirm effective knockdown of Ets1 by QRT-PCR and western analysis (Fig 7) . Silencing Ets1 results in a statistically significant decrease in Twist1 mRNA and protein levels. Taken together, ChIP and siRNA data confirm that Ets1 is a transcriptional activator of Twist1 in lung cancer cell lines.
Discussion
Little is known about the transcription factors that regulate Twist1 expression in lung and other cancers. To our knowledge, we show for the first time, that in lung cancer cell lines, Ets1 regulates Twist1 expression. We hypothesized that Ets proteins regulate genes involved in EMT such as Twist1, thereby promoting lung cancer progression and metastasis. In the proximal -2 kb of the murine Twist1 promoter, there are 34 putative Ets binding sites, of which approximately one-third is conserved between mouse and human . We selected Ets1 as a candidate activator of Twist1 transcription in lung tumor specimens since this transcription factor has been previously implicated in tumor invasion and poor prognosis in lung cancer.
Lymph nodes are often the first site of metastasis in lung cancer. Detection of lymph node metastasis is a key factor in staging and prognosis. For our studies, we used tissue specimens and cell lines derived from a mouse model of lung metastasis driven by conditionally activated Kras with concurrent tumor suppressor Lkb1 loss (Ji et al., 2007) . Inactivating mutations of Lkb1 and activating mutations of Kras occur together frequently in human disease (Makowski and Hayes, 2008) . Similar to the pattern of LN metastasis in human lung cancer, this model has a 60% penetrance of regional LN and distant metastasis.
Twist1 appears to be a pro-metastasis gene that specifically promotes tumorigenesis by inducing tumor cell EMT. Twist1 is a highly conserved transcription factor belonging to the family of basic helix-loop-helix (bHLH) proteins (Bialek et al., 2004; Cheng et al., 2008 ) Like many oncogenes, Twist1 is likely to exert similar biological activities during tumor metastasis as it does in normal development. In mice, Twist1 was shown to be required for head mesenchyme, somites and limb buds development (Lee et al., 2009 ). Mice lacking Twist1 die at E10.5 secondary to defects in cell migration confirming its important role in development and differentiation (Baylies and Bate, 1996). Therefore we anticipated that alteration in Twist1 expression would influence cell migration and/or invasion.
Herein, we report that Ets proteins participate in transcriptional regulation of Twist1 using both murine and human lung cancer cell lines as experimental models. Using the existing mRNA expression database of metastatic versus non-metastatic mouse tumor specimens, we confirm increased Ets1, but not Pea3, mRNA expression by QRT-PCR in Kras G12D /Lkb1 L/L (metastatic mouse model) compared to Kras G12D (non-metastatic mouse model) primary tumors. We determined by ChIP assays that Ets1 binds to the Twist1 promoter in mouse and human cell lines. Silencing Ets1 results in a statistically significant decrease in Twist1 mRNA and protein indicating that Ets1 is likely a direct transcriptional activator of Twist1 in lung cancer cell lines. It is likely that other Ets proteins, cis-elements, and transcription factors are involved in Twist1 regulation in lung tumorigenesis as suggested by studies of these proteins in other cancer cell lines. In mouse mammary epithelial cells, both Pea3 and Ets1 activate the Twist1 promoter in concert with steroid receptor coactivator-1 (Src-1) (Howe et al., 2003) . Src-1 has been found to coactivate Twist1 transcription through physical interactions with Pea3 at the proximal Twist1 promoter, thereby promoting breast cancer metastasis ). The significance of multiple Ets sites within the Twist1 promoter is unknown. In the TβR-II (type II TGFβ receptor) promoter 2 Ets sites are required for a synergistic response to Elf3, Ets1, and Pea3 (Kopp et al., 2004) , suggesting the likelihood that multiple Ets sites are occupied and active in Twist1 expression.
We characterized the expression pattern of Ets1 and Twist1 in primary tumors and metastatic lymph nodes. Twist1 staining positively correlates with Ets1 immunostaining in both murine and human tissues. Furthermore, Ets1 and Twist1 protein expression match in terms of expressing cells. In Twist1-positive stromal cells, Ets1 expression is detected in the stroma. In specimens in which Twist1 is detected in tumor epithelial nuclei, Ets1 is detected in tumor epithelial nuclei. In some cases, the tumor epithelial cells are strongly stained, particularly at the margins of the tumor.
We show that Twist1-positive cells are preferentially localized in stroma adjacent to clusters of cancer cells. Although these cells have a fibroblast-like morphology, it is possible that they are, or are derived from cancer cells that have undergone a morphological change via EMT. Modified fibroblasts, variably called myofibroblasts, reactive stroma, or cancer-associated fibroblasts, are thought to play a central role in tumor-stroma interactions (Kalluri and Zeisberg, 2006) . The concept that cancer cells become metastatic via EMT is based on observations that acquisition of mesenchymal markers [such as vimentin and S100A4 (also known as fibroblast-specific protein 1 (FSP1)] by epithelial carcinoma cells and loss of epithelial cell adhesion molecules [such as E-cadherin] is associated with increased metastatic potential. Further characterization of these Twist1-positive epithelial and stromal cells will be the focus of future studies.
Previous studies in NCI-H1299 cells show that siRNA-mediated Twist1 repression decreases N-cadherin and increases E-cadherin expression resulting in decreased migration and invasion . We now show that silencing Twist1 or Ets1 decreases migration and invasion in both Kras G12D /Lkb1 L/L primary and metastatic-derived cell lines.
Several transcription factors, including Twist1, Snail, and SIP1 repress Ecadherin expression and are thought to induce EMT . Among the transcription factors we examined, Twist1 and Ets1 are significantly upregulated in metastatic compared to non-metastatic tumors. Therapeutic targeting of these E-cadherin repressors/or their regulators, such as Ets1, could be useful to impair EMT and thus metastatic spreading. Identifying upstream Twist1 activators and downstream targets will be critical for understanding the molecular mechanisms underlying metastasis and in finding new targets in cancer treatment.
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MATERIALS AND METHODS
Gene expression Microarray Analysis
Gene expression profiles comparing Kras G12D primary tumors (9 tumors), Kras G12D /Lkb1 L/L primary tumors (9 tumors) and Kras G12D /Lkb1 L/L metastasis (16 lymph node and distant sites) have been previously characterized (Carretero et al., 2010) . As described by Carretero et al, using a two-class unpaired differential expression analysis and a false-discovery rate (FDR) of < 0.01, signatures reflecting (1) 
Immunohistochemistry
Archived paraformaldehyde-fixed, paraffin-embedded human lung adenocarcinomas were studied. A pathologist reviewed H&E stained sections and assigned a grade of well-, moderate-, or poorly-differentiated tumors (Travis et al., 1999) . Thyroid transcription factor (Nkx2.1, TTF-1) immunohistochemistry confirmed lung origin of specimens (Kaufmann et al., 2000) . Antigen retrieval for Ets1 and Twist1 is Vector Antigen Unmasking Solution (H3300) (microwave low-power, 15 min) (Ge et al., 2006; Namimatsu et al., 2005) . Sections were incubated with primary antibody [mouse monoclonal anti-Ets1 (sc-56674, Santa Cruz Biotechnology) or mouse monoclonal anti-Twist1 (sc-81417, Santa Cruz Biotechnology)] in PBS (4˚C, 16 hr). Antibody binding was detected using Vectastain Elite ABC kit with DAB as the substrate. Control slides lacking primary antibody were included in all procedures. Sections were counterstained with methyl green, hematoxylin, or left unstained and photographed in a Leitz Aristopan microscope using ImagePro software. Photographs shown are representative from n=30 samples for Twist1 and n=15 for Ets1.
For mouse lung cancer specimens (n=3 for each model), formalin-fixed paraffin embedded tissue were sectioned at 5 μm. Slides were deparaffinized in xylene and rehydrated sequentially in ethanol. Similar methods were used for TTF-1, Twist1, Ets1 and Pea3 [mouse monoclonal anti-PEA3 antibody (sc-113, Santa Cruz Biotechnology)] immunostaining except that antibody binding was detected using Vector Mouse on Mouse Kit with DAB as the substrate.
Characterization and Culture of the Cell Lines
Human NSCLC cell lines were selected based on mRNA and protein analyses showing that NCI-H1299 cells (metastatic lymph node-derived) express high Ets1 levels (Sloan et al., 2009 ); A549 cells (primary lung carcinoma-derived) express lower Ets1 levels (Ko et al., 1999) Tumor-derived cell lines from mice with different abilities to generate lymph node metastases were used. KW-634 cells are primary tumor-derived cell lines from Kras G12D mice; KW-821 (T) cells are primary tumor-derived and KW-821 (LN) cells are metastatic lymph node-derived cell lines from Kras G12D /Lkb1 L/L mice. NCI-H1299, KW-634 and KW-821 (T and LN) cells were maintained in RPMI 1640 medium (Invitrogen) with 10 mM HEPES; A549 cells were maintained in DMEM (Invitrogen). Cells were maintained in media containing 10% FBS, 2 mM glutamine, 100 units/ml penicillin G, and 100 µg/ml streptomycin sulfate, incubated at 37°C in 5% CO 2 , and harvested at 80% confluence for experiments.
RNA Purification
Total RNA was isolated from cell lines with TRIzol (Invitrogen) and treated for DNA contamination using DNA-free (Ambion). 500 ng RNA was reverse-transcribed using TaqMan Protein Purification, Western Blots, and Protein Densitometry Cell monolayers were trypsinized, washed in PBS, centrifuged, resuspended in lysis buffer with protease inhibitors, and incubated with rotation (4°C, 60 min). Lysate was centrifuged (10 minutes, 13,000 rpm, 4°C). Supernatant (20-50 μg protein) was electrophoresed on a 12% polyacrylamide gel and transferred to PVDF membranes. Membranes were blocked in 1X TBST containing 5% dry milk (1h, RT), exposed overnight (4°C) to mouse anti-Twist1 antibody (1:1000) followed by anti-mouse secondary antibody (1:10000, 1h, RT) or rabbit polyclonal anti-Ets1 antibody (1:1000) (sc-350, Santa Cruz Biotechnology) and anti-rabbit secondary antibody (1:20000). Immunoblots were probed for β-actin to control for equal loading. Binding of labeled horseradish peroxidase-secondary antibodies was detected with Super-Signal West Pico Chemiluminescent Substrate (Pierce). All experiments were performed in triplicate.
Chromatin Immunoprecipitation Assays
Cells were fixed with 1% formaldehyde, incubated (37°C, 15 mins), washed with PBS, resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8, 1 mM PMSF, 1 mM pepstatin A, and 1 mM aprotinin), and sonicated on ice to 500 to1000 base-pair fragments (Power 5, 5 cycles of 5 mins, 25 s on, 5 s off; Fisher Scientific sonicator). Lysate was centrifuged (RT, 4000 rpm, 5mins). Supernatant was divided into aliquots, one aliquot stored as input DNA. 3 μg of anti-Ets1 or nonspecific IgG (mouse IgG for Ets1) antibodies were added to other aliquots. Dilution buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA pH 8, 20 mM Tris-HCl pH 8, and 150 mM NaCl, 1mM PMSF, 1mM Aprotinin) was added and samples were incubated (4°C, overnight) with rotation.
AG beads (Santa Cruz Biotechnology, Inc.), BSA (100 μg/ml), and salmon sperm (500 μg/ml) were added to samples. Samples were rotated (4°C, 2 hrs) and centrifuged (4000 rpm, 2 mins). Pellets were washed in buffer (1% Triton X-100, 0.1% SDS, 150 mM NaCl, 2mM EDTA pH 8, 20 mM Tris-HCl pH 8, 1 1 mM PMSF, 1 mM Aprotinin), then with final wash buffer (1% Triton X-100, 0.1% SDS, 500 mM NaCl, 2 mM EDTA pH 8, 20 mM Tris-HCl pH 8). Immune complexes were eluted with buffer (1% SDS, 100 mM NaHCO3), incubated with rotation (RT, 15 mins), and centrifuged (4000 rpm, 2 mins). Proteinase K (500 μg/ml) and RNase A (500 μg/ml) were added to supernatants and input DNA, then incubated (37°C, 30 mins). Cross-links were reversed (65°C, overnight) and DNA was purified.
DNA fragments were analyzed by PCR for Twist1. Input DNA served as positive controls; IgG-precipitated DNA and human/mouse Twist1 promoter sequences to which Ets1 do not bind served as negative controls. Primers for mouse Twist1 ETS site: 5"GGTTCGCAGGACGAATTGTT3"; 5"AGGGACTTTTCGAAGTTTTATAGGAA3". Primers for human Twist1 ETS site: 5"AGCCCCAGCAATCCAAATC3"; 5"GATGTCTCATCTCGCCCAAGAG3". Negative control primers: (human: 5"CTGCAGACTTGGAGGCTCTT3"; 5"GTCAGGCCAATGACACTGCT3"; mouse: 5"TGGACAGAGATTCCCAGAGG3"; 5"CTATCAGAATGCAGAGGTGTGG3"). 
